The District Consumer Disputes Redressal Commission in Chandigarh has held Fortis Hospital in Mohali and one of its doctors guilty of medical negligence. The commission has ordered the hospital to pay a compensation of Rs 50 lakh along with 9% interest per annum to the widow of a patient who died during treatment. The patient, Harit Sharma, was admitted to the hospital in 2021 with an acute gastric problem. Despite initial improvement, his condition deteriorated due to alleged negligence in a medical procedure called tapping, which was done to remove ascites from his stomach.

The patient’s wife, Priyanka Sharma, filed a complaint with the commission, alleging that the hospital staff was negligent in performing the tapping procedure, which led to a drastic drop in her husband’s oxygen levels. She claimed that her husband was fully conscious and aware of the mistake made by the hospital staff, and he even wrote a note to her conveying what had happened during the procedure. Unfortunately, Harit Sharma passed away on August 2, 2021.

The hospital authorities refuted the allegations, claiming that there was no negligence on their part and that there was no expert evidence to prove otherwise. However, the commission found the hospital liable for medical negligence, deficiency in service, and unfair trade practice. The commission ordered the hospital to pay a lump sum compensation of Rs 50 lakh along with 9% interest per annum from the date of the patient’s death.

The commission’s decision was based on the fact that the hospital had failed to provide adequate care and treatment to the patient, leading to his death. The commission also took into account the dying declaration made by the patient, which provided evidence of the hospital’s negligence. The order highlights the importance of hospitals and medical professionals providing adequate care and treatment to patients, and the consequences of failing to do so. The case serves as a reminder of the need for accountability and transparency in the medical profession.

Fortis and Agilus have partnered to enhance genomic testing capabilities with the installation of a second Genexus system. This move is expected to significantly improve the speed and accuracy of cancer diagnosis. The Genexus system is a next-generation sequencing (NGS) platform that enables comprehensive genomic profiling, allowing for the analysis of multiple genes and biomarkers in a single test.

The addition of a second Genexus system will increase Fortis’s testing capacity, enabling the processing of a higher volume of samples and reducing turnaround times. This is particularly crucial in cancer diagnosis, where timely and accurate results are essential for guiding treatment decisions. With the enhanced capacity, Fortis and Agilus aim to provide faster and more accurate diagnosis, ultimately improving patient outcomes.

The Genexus system offers several advantages, including its ability to analyze multiple genes and biomarkers simultaneously, reducing the need for multiple tests and minimizing tissue requirements. This comprehensive approach enables the identification of genetic mutations and variations that can inform treatment strategies, including targeted therapies and immunotherapies.

The partnership between Fortis and Agilus is built on a shared commitment to improving cancer diagnosis and treatment. Agilus, a leading provider of genetic testing solutions, has developed the Genexus system to address the growing need for advanced genomic testing. Fortis, a prominent healthcare provider, has recognized the potential of the Genexus system to enhance its diagnostic capabilities and has invested in the technology to improve patient care.

The installation of the second Genexus system is a significant milestone in the partnership between Fortis and Agilus. It demonstrates their shared commitment to leveraging cutting-edge technology to improve cancer diagnosis and treatment. With the enhanced genomic testing capabilities, Fortis and Agilus are poised to make a meaningful impact on patient care, enabling faster and more accurate diagnosis, and ultimately improving treatment outcomes.

In conclusion, the partnership between Fortis and Agilus has resulted in the installation of a second Genexus system, strengthening their genomic testing capabilities and enabling faster cancer diagnosis. The enhanced capacity and accuracy of the Genexus system will have a significant impact on patient care, providing timely and accurate results that can inform treatment decisions. As the demand for advanced genomic testing continues to grow, the collaboration between Fortis and Agilus is well-positioned to drive innovation and improve patient outcomes in the field of cancer diagnosis and treatment.